The iR(2) regimen(ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphoma
Ramchandren, R Johnson, P Ghosh, N Ruan, J Ardeshna, M Johnson, R Verhoef, G Cunningham, D de Vos, S Kassam, S
Ramchandren, R
Johnson, P
Ghosh, N
Ruan, J
Ardeshna, M
Johnson, R
Verhoef, G
Cunningham, D
de Vos, S
Kassam, S
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna K, Johnson R, et al. The iR(2) regimen(ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphoma. Blood. 2018;132.